RSV Vaccine Products Possible in Next Few Years: Kalorama21 Jan 2011 • by Natalie Aster
LONDON —The success of vaccine products in recent years has spurred companies to take on new diseases and, according to Kalorama Information, Respiratory Syncytial Virus (RSV) could be one of those. The healthcare market research publisher says in its survey of emerging vaccine products titled: “What's Next in Vaccines? HIV, Malaria, Rabies, MRSA, and 30 Other Vaccine Targets in the 2010-2020 Pipeline”, that there could be an RSV vaccine market worth hundreds of millions of dollars in six years.
Respiratory Syncytial Virus affects more than 60 million children each year. It causes respiratory tract infections and can be fatal if untreated. There is no direct treatment for RSV other than supportive care to assist breathing and some partial therapies that can stave off the condition. MedImmune’s Synagis, a monoclonal antibody introduced in 1998 and the current standard of care for RSV, sold more than $1 billion in 2009, according to Kalorama.
“Synagis is not a vaccine and delivers antibodies that prevent RSV for only 30 days.” said Melissa Elder, analyst for Kalorama Information. “A vaccine could potentially provide longer protection and is therefore the subject of ongoing research.”
Sanofi Pasteur is currently in Phase II studies of one vaccine candidate while other developers are in earlier stages of testing. According to Kalorama, if an RSV vaccine product is introduced in 2014, sales are expected to grow quickly, reaching $400 million in 2016 and $1.4 billion in 2020.
RSV is just one of many diseases for which Kalorama projects a vaccine in the near future. Kalorama Information's report “What's Next in Vaccines? HIV, Malaria, Rabies, MRSA, and 30 Other Vaccine Targets in the 2010-2020 Pipeline” forecasts emerging vaccine markets through 2020, previews the product pipeline and details the major players in the industry.
What's Next in Vaccines? HIV, Malaria, Rabies, MRSA, and 30 Other Vaccine Targets in the 2010-2020 Pipeline
Date: Feb, 2010
Price: US$ 4,200.00
To order the report or ask for sample pages contact email@example.com